The impact of obesity on heart failure.

Curr Opin Cardiol

Division of Cardiology, Department of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.

Published: March 2017

Purpose Of Review: Obesity, a growing global health problem, contributes to the development of heart failure. However, increased BMI seems protective for those with established disease, a phenomenon known as the 'obesity paradox'. In this review, we outline the mechanism through which obesity can contribute to the development of heart failure, explore the concept of obesity paradox, and highlight the challenges that obesity presents for advanced heart failure therapy.

Recent Findings: Although the mechanism underlying the obesity paradox is complex, meta-analysis shows that intentional weight loss through bariatric surgery can indeed improve cardiac structure and function. With regard to ventricular assist device therapy in obese patients, recent studies demonstrate that while obesity was indeed associated with higher likelihood of complications, there were no statistically significant differences in terms of mortality or delisting from cardiac transplant waiting list.

Summary: Obesity is strongly associated with the development of heart failure, through direct and indirect mechanisms. Although clear consensus regarding weight reduction in this patient population is lacking, there is mounting clinical evidence that intentional weight loss may be beneficial, in spite of the well-recognized obesity paradox, particularly as the presence of obesity presents unique challenges in the advanced therapy of heart failure patients.

Download full-text PDF

Source
http://dx.doi.org/10.1097/HCO.0000000000000370DOI Listing

Publication Analysis

Top Keywords

heart failure
24
development heart
12
obesity paradox
12
obesity
9
obesity presents
8
intentional weight
8
weight loss
8
obesity associated
8
heart
6
failure
6

Similar Publications

Effect of cardiomyocyte-specific lipid phosphate phosphatase 3 overexpression on high-fat diet-induced cardiometabolic dysfunction in mice.

Am J Physiol Heart Circ Physiol

January 2025

Department of Biochemistry and Molecular Biology, Dalhousie University, Dalhousie Medicine New Brunswick, 355 Campus Ring Road, Saint John, New Brunswick, E2L 4L5, Canada.

Lipid phosphate phosphatase 3 (LPP3) is a membrane-bound enzyme that hydrolyzes lipid phosphates including the bioactive lipid, lysophosphatidic acid (LPA). Elevated circulating LPA production and cellular LPA signaling are implicated in obesity-induced metabolic and cardiac dysfunction. Deletion of LPP3 in the cardiomyocyte increases circulating LPA levels and causes heart failure and mitochondrial dysfunction in mice.

View Article and Find Full Text PDF

Clarifying the inceptive pathophysiology of hypertensive heart disease helps to impede the disease progression. Through coarctation of the infrarenal abdominal aorta (AA), we induced hypertension in minipigs and evaluated physiological reactions and morpho-functional changes of the heart. Moderate aortic coarctation was achieved with approximately 30 mmHg systolic pressure gradient in minipigs.

View Article and Find Full Text PDF

Introduction: Heart failure (HF) is a chronic condition with an unpredictable trajectory, making effective communication between patients and healthcare providers crucial for optimizing outcomes. This study aims to investigate and compare the communication needs regarding HF trajectory and palliative care between patients and healthcare providers and to identify factors associated with the communication needs of patients with HF.

Methods: A cross-sectional study design was employed, involving 100 patients with HF and 35 healthcare providers.

View Article and Find Full Text PDF

Deubiquitinating enzymes (DUBs) are integral regulators of protein stability. Among these, Ubiquitin-specific protease 18 (USP18) has emerged as a potential therapeutic target for heart failure. However, its precise role in atherosclerosis remains to be comprehensively understood.

View Article and Find Full Text PDF

Importance: Cardiovascular health outcomes associated with noncigarette tobacco products (cigar, pipe, and smokeless tobacco) remain unclear, yet such data are required for evidence-based regulation.

Objective: To investigate the association of noncigarette tobacco products with cardiovascular health outcomes.

Design, Setting, And Participants: This cohort study was conducted within the Cross Cohort Collaboration Tobacco Working Group by harmonizing tobacco-related data and conducting a pooled analysis from 15 US-based prospective cohorts with data on the use of at least 1 noncigarette tobacco product ranging between 1948 and 2015.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!